APO Research
Talk to an analyst

APO RESEARCH · REPORT

Equine Rabies Immunoglobulin (ERIG)

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Equine Rabies Immunoglobulin (ERIG) Market Outlook and Growth Opportunities 2026

2 January 2026195 pages

Choose your research edition.

Industry ResearchEquine Rabies Immunoglobulin (ERIG) Industry Research Report 2026119 pages · $2,950 USDIndustry Growth & TrendsGlobal Equine Rabies Immunoglobulin (ERIG) Industry Growth and Trends Forecast to 203295 pages · $3,450 USDMarket StructureGlobal Equine Rabies Immunoglobulin (ERIG) Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032182 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Equine Rabies Immunoglobulin (ERIG) Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Equine Rabies Immunoglobulin (ERIG) Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global Equine Rabies Immunoglobulin (ERIG) market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Equine Rabies Immunoglobulin (ERIG) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Equine Rabies Immunoglobulin (ERIG) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Equine Rabies Immunoglobulin (ERIG) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Equine Rabies Immunoglobulin (ERIG) market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Equine Rabies Immunoglobulin (ERIG) market include Wuhan Institute of Biological Products, Serum China, Lanzhou Institute of Biological Products, Premium Serums, Haffkine Bio-Pharmaceutical and Bharat Serums, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Equine Rabies Immunoglobulin (ERIG) market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Equine Rabies Immunoglobulin (ERIG) and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Equine Rabies Immunoglobulin (ERIG) sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Equine Rabies Immunoglobulin (ERIG) market size, projected growth trends, production technologies, key applications, and end-use industries.

Equine Rabies Immunoglobulin (ERIG) Segment by Company

Wuhan Institute of Biological Products

Serum China

Lanzhou Institute of Biological Products

Premium Serums

Haffkine Bio-Pharmaceutical

Bharat Serums

Equine Rabies Immunoglobulin (ERIG) Segment by Type

1500IU

1000IU

400IU

Other

Equine Rabies Immunoglobulin (ERIG) Segment by Application

Category II Exposure

Category III Exposure

Equine Rabies Immunoglobulin (ERIG) Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Equine Rabies Immunoglobulin (ERIG) status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Equine Rabies Immunoglobulin (ERIG) market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Equine Rabies Immunoglobulin (ERIG) significant trends, drivers, influence factors in global and regions.

6. To analyze Equine Rabies Immunoglobulin (ERIG) competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Equine Rabies Immunoglobulin (ERIG) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Equine Rabies Immunoglobulin (ERIG) and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Equine Rabies Immunoglobulin (ERIG).

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Equine Rabies Immunoglobulin (ERIG) market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Equine Rabies Immunoglobulin (ERIG) industry.

Chapter 3: Detailed analysis of Equine Rabies Immunoglobulin (ERIG) manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Equine Rabies Immunoglobulin (ERIG) in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Equine Rabies Immunoglobulin (ERIG) in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Equine Rabies Immunoglobulin (ERIG) Industry Trends Table 2. Equine Rabies Immunoglobulin (ERIG) Industry Drivers Table 3. Equine Rabies Immunoglobulin (ERIG) Industry Opportunities and Challenges Table 4. Equine Rabies Immunoglobulin (ERIG) Industry Restraints Table 5. Global Equine Rabies Immunoglobulin (ERIG) Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Equine Rabies Immunoglobulin (ERIG) Revenue Share by Company (2021-2026) Table 7. Global Equine Rabies Immunoglobulin (ERIG) Sales Volume by Company (K Tons) & (2021-2026) Table 8. Global Equine Rabies Immunoglobulin (ERIG) Sales Volume Share by Company (2021-2026) Table 9. Global Equine Rabies Immunoglobulin (ERIG) Average Price (US$/Ton) of Company (2021-2026) Table 10. Global Equine Rabies Immunoglobulin (ERIG) Company Ranking, (2024-2026) & (USD Million) Table 11. Global Equine Rabies Immunoglobulin (ERIG) Key Company Manufacturing Base & Headquarters Table 12. Global Equine Rabies Immunoglobulin (ERIG) Company, Product Type & Application Table 13. Global Equine Rabies Immunoglobulin (ERIG) Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Equine Rabies Immunoglobulin (ERIG) by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of 1500IU Table 18. Significant Companies of 1000IU Table 19. Significant Companies of 400IU Table 20. Significant Companies of Other Table 21. Global Equine Rabies Immunoglobulin (ERIG) Sales Volume by Type 2021 VS 2025 VS 2032 (K Tons) Table 22. Global Equine Rabies Immunoglobulin (ERIG) Sales Volume by Type (2021-2026) & (K Tons) Table 23. Global Equine Rabies Immunoglobulin (ERIG) Sales Volume by Type (2027-2032) & (K Tons) Table 24. Global Equine Rabies Immunoglobulin (ERIG) Sales Volume Share by Type (2021-2026) Table 25. Global Equine Rabies Immunoglobulin (ERIG) Sales Volume Share by Type (2027-2032) Table 26. Global Equine Rabies Immunoglobulin (ERIG) Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Equine Rabies Immunoglobulin (ERIG) Sales Value by Type (2021-2026) & (US$ Million) Table 28. Global Equine Rabies Immunoglobulin (ERIG) Sales Value by Type (2027-2032) & (US$ Million) Table 29. Global Equine Rabies Immunoglobulin (ERIG) Sales Value Share by Type (2021-2026) Table 30. Global Equine Rabies Immunoglobulin (ERIG) Sales Value Share by Type (2027-2032) Table 31. Significant Companies of Category II Exposure Table 32. Significant Companies of Category III Exposure Table 33. Global Equine Rabies Immunoglobulin (ERIG) Sales Volume by Application 2021 VS 2025 VS 2032 (K Tons) Table 34. Global Equine Rabies Immunoglobulin (ERIG) Sales Volume by Application (2021-2026) & (K Tons) Table 35. Global Equine Rabies Immunoglobulin (ERIG) Sales Volume by Application (2027-2032) & (K Tons) Table 36. Global Equine Rabies Immunoglobulin (ERIG) Sales Volume Share by Application (2021-2026) Table 37. Global Equine Rabies Immunoglobulin (ERIG) Sales Volume Share by Application (2027-2032) Table 38. Global Equine Rabies Immunoglobulin (ERIG) Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 39. Global Equine Rabies Immunoglobulin (ERIG) Sales Value by Application (2021-2026) & (US$ Million) Table 40. Global Equine Rabies Immunoglobulin (ERIG) Sales Value by Application (2027-2032) & (US$ Million) Table 41. Global Equine Rabies Immunoglobulin (ERIG) Sales Value Share by Application (2021-2026) Table 42. Global Equine Rabies Immunoglobulin (ERIG) Sales Value Share by Application (2027-2032) Table 43. Global Equine Rabies Immunoglobulin (ERIG) Sales by Region: 2021 VS 2025 VS 2032 (K Tons) Table 44. Global Equine Rabies Immunoglobulin (ERIG) Sales by Region (2021-2026) & (K Tons) Table 45. Global Equine Rabies Immunoglobulin (ERIG) Sales Market Share by Region (2021-2026) Table 46. Global Equine Rabies Immunoglobulin (ERIG) Sales by Region (2027-2032) & (K Tons) Table 47. Global Equine Rabies Immunoglobulin (ERIG) Sales Market Share by Region (2027-2032) Table 48. Global Equine Rabies Immunoglobulin (ERIG) Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 49. Global Equine Rabies Immunoglobulin (ERIG) Sales Value by Region (2021-2026) & (US$ Million) Table 50. Global Equine Rabies Immunoglobulin (ERIG) Sales Value Share by Region (2021-2026) Table 51. Global Equine Rabies Immunoglobulin (ERIG) Sales Value by Region (2027-2032) & (US$ Million) Table 52. Global Equine Rabies Immunoglobulin (ERIG) Sales Value Share by Region (2027-2032) Table 53. Global Equine Rabies Immunoglobulin (ERIG) Market Average Price (US$/Ton) by Region (2021-2026) Table 54. Global Equine Rabies Immunoglobulin (ERIG) Market Average Price (US$/Ton) by Region (2027-2032) Table 55. Global Equine Rabies Immunoglobulin (ERIG) Sales by Country: 2021 VS 2025 VS 2032 (K Tons) Table 56. Global Equine Rabies Immunoglobulin (ERIG) Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 57. Global Equine Rabies Immunoglobulin (ERIG) Sales by Country (2021-2026) & (K Tons) Table 58. Global Equine Rabies Immunoglobulin (ERIG) Sales Market Share by Country (2021-2026) Table 59. Global Equine Rabies Immunoglobulin (ERIG) Sales by Country (2027-2032) & (K Tons) Table 60. Global Equine Rabies Immunoglobulin (ERIG) Sales Market Share by Country (2027-2032) Table 61. Global Equine Rabies Immunoglobulin (ERIG) Sales Value by Country (2021-2026) & (US$ Million) Table 62. Global Equine Rabies Immunoglobulin (ERIG) Sales Value Market Share by Country (2021-2026) Table 63. Global Equine Rabies Immunoglobulin (ERIG) Sales Value by Country (2027-2032) & (US$ Million) Table 64. Global Equine Rabies Immunoglobulin (ERIG) Sales Value Market Share by Country (2027-2032) Table 65. Wuhan Institute of Biological Products Company Information Table 66. Wuhan Institute of Biological Products Business Overview Table 67. Wuhan Institute of Biological Products Equine Rabies Immunoglobulin (ERIG) Sales (K Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 68. Wuhan Institute of Biological Products Equine Rabies Immunoglobulin (ERIG) Product Portfolio Table 69. Wuhan Institute of Biological Products Recent Development Table 70. Serum China Company Information Table 71. Serum China Business Overview Table 72. Serum China Equine Rabies Immunoglobulin (ERIG) Sales (K Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 73. Serum China Equine Rabies Immunoglobulin (ERIG) Product Portfolio Table 74. Serum China Recent Development Table 75. Lanzhou Institute of Biological Products Company Information Table 76. Lanzhou Institute of Biological Products Business Overview Table 77. Lanzhou Institute of Biological Products Equine Rabies Immunoglobulin (ERIG) Sales (K Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 78. Lanzhou Institute of Biological Products Equine Rabies Immunoglobulin (ERIG) Product Portfolio Table 79. Lanzhou Institute of Biological Products Recent Development Table 80. Premium Serums Company Information Table 81. Premium Serums Business Overview Table 82. Premium Serums Equine Rabies Immunoglobulin (ERIG) Sales (K Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 83. Premium Serums Equine Rabies Immunoglobulin (ERIG) Product Portfolio Table 84. Premium Serums Recent Development Table 85. Haffkine Bio-Pharmaceutical Company Information Table 86. Haffkine Bio-Pharmaceutical Business Overview Table 87. Haffkine Bio-Pharmaceutical Equine Rabies Immunoglobulin (ERIG) Sales (K Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 88. Haffkine Bio-Pharmaceutical Equine Rabies Immunoglobulin (ERIG) Product Portfolio Table 89. Haffkine Bio-Pharmaceutical Recent Development Table 90. Bharat Serums Company Information Table 91. Bharat Serums Business Overview Table 92. Bharat Serums Equine Rabies Immunoglobulin (ERIG) Sales (K Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 93. Bharat Serums Equine Rabies Immunoglobulin (ERIG) Product Portfolio Table 94. Bharat Serums Recent Development Table 95. Key Raw Materials Table 96. Raw Materials Key Suppliers Table 97. Equine Rabies Immunoglobulin (ERIG) Distributors List Table 98. Equine Rabies Immunoglobulin (ERIG) Customers List Table 99. Research Programs/Design for This Report Table 100. Authors List of This Report Table 101. Secondary Sources Table 102. Primary Sources List of Figures Figure 1. Equine Rabies Immunoglobulin (ERIG) Product Image Figure 2. Global Equine Rabies Immunoglobulin (ERIG) Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Equine Rabies Immunoglobulin (ERIG) Sales Value (2021-2032) & (US$ Million) Figure 4. Global Equine Rabies Immunoglobulin (ERIG) Sales (2021-2032) & (K Tons) Figure 5. Global Equine Rabies Immunoglobulin (ERIG) Sales Average Price (US$/Ton) & (2021-2032) Figure 6. Global Equine Rabies Immunoglobulin (ERIG) Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. 1500IU Image Figure 10. 1000IU Image Figure 11. 400IU Image Figure 12. Other Image Figure 13. Global Equine Rabies Immunoglobulin (ERIG) Sales Volume by Type (2021 VS 2025 VS 2032) & (K Tons) Figure 14. Global Equine Rabies Immunoglobulin (ERIG) Sales Volume Share 2021 VS 2025 VS 2032 Figure 15. Global Equine Rabies Immunoglobulin (ERIG) Sales Volume Share by Type (2021-2032) Figure 16. Global Equine Rabies Immunoglobulin (ERIG) Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Equine Rabies Immunoglobulin (ERIG) Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Equine Rabies Immunoglobulin (ERIG) Sales Value Share by Type (2021-2032) Figure 19. Category II Exposure Image Figure 20. Category III Exposure Image Figure 21. Global Equine Rabies Immunoglobulin (ERIG) Sales Volume by Application (2021 VS 2025 VS 2032) & (K Tons) Figure 22. Global Equine Rabies Immunoglobulin (ERIG) Sales Volume Share 2021 VS 2025 VS 2032 Figure 23. Global Equine Rabies Immunoglobulin (ERIG) Sales Volume Share by Application (2021-2032) Figure 24. Global Equine Rabies Immunoglobulin (ERIG) Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 25. Global Equine Rabies Immunoglobulin (ERIG) Sales Value Share 2021 VS 2025 VS 2032 Figure 26. Global Equine Rabies Immunoglobulin (ERIG) Sales Value Share by Application (2021-2032) Figure 27. Global Equine Rabies Immunoglobulin (ERIG) Sales by Region: 2021 VS 2025 VS 2032 (K Tons) Figure 28. Global Equine Rabies Immunoglobulin (ERIG) Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 29. Global Equine Rabies Immunoglobulin (ERIG) Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 30. Global Equine Rabies Immunoglobulin (ERIG) Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 31. North America Equine Rabies Immunoglobulin (ERIG) Sales Value (2021-2032) & (US$ Million) Figure 32. North America Equine Rabies Immunoglobulin (ERIG) Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Europe Equine Rabies Immunoglobulin (ERIG) Sales Value (2021-2032) & (US$ Million) Figure 34. Europe Equine Rabies Immunoglobulin (ERIG) Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Asia-Pacific Equine Rabies Immunoglobulin (ERIG) Sales Value (2021-2032) & (US$ Million) Figure 36. Asia-Pacific Equine Rabies Immunoglobulin (ERIG) Sales Value Share by Country (%), 2025 VS 2032 Figure 37. South America Equine Rabies Immunoglobulin (ERIG) Sales Value (2021-2032) & (US$ Million) Figure 38. South America Equine Rabies Immunoglobulin (ERIG) Sales Value Share by Country (%), 2025 VS 2032 Figure 39. Middle East & Africa Equine Rabies Immunoglobulin (ERIG) Sales Value (2021-2032) & (US$ Million) Figure 40. Middle East & Africa Equine Rabies Immunoglobulin (ERIG) Sales Value Share by Country (%), 2025 VS 2032 Figure 41. USA Equine Rabies Immunoglobulin (ERIG) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. USA Equine Rabies Immunoglobulin (ERIG) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. USA Equine Rabies Immunoglobulin (ERIG) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. Canada Equine Rabies Immunoglobulin (ERIG) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. Canada Equine Rabies Immunoglobulin (ERIG) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. Canada Equine Rabies Immunoglobulin (ERIG) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Mexico Equine Rabies Immunoglobulin (ERIG) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Mexico Equine Rabies Immunoglobulin (ERIG) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Mexico Equine Rabies Immunoglobulin (ERIG) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Germany Equine Rabies Immunoglobulin (ERIG) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Germany Equine Rabies Immunoglobulin (ERIG) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Germany Equine Rabies Immunoglobulin (ERIG) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. France Equine Rabies Immunoglobulin (ERIG) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. France Equine Rabies Immunoglobulin (ERIG) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. France Equine Rabies Immunoglobulin (ERIG) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. U.K. Equine Rabies Immunoglobulin (ERIG) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. U.K. Equine Rabies Immunoglobulin (ERIG) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. U.K. Equine Rabies Immunoglobulin (ERIG) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Italy Equine Rabies Immunoglobulin (ERIG) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Italy Equine Rabies Immunoglobulin (ERIG) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Italy Equine Rabies Immunoglobulin (ERIG) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Spain Equine Rabies Immunoglobulin (ERIG) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Spain Equine Rabies Immunoglobulin (ERIG) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Spain Equine Rabies Immunoglobulin (ERIG) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Russia Equine Rabies Immunoglobulin (ERIG) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Russia Equine Rabies Immunoglobulin (ERIG) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Russia Equine Rabies Immunoglobulin (ERIG) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Netherlands Equine Rabies Immunoglobulin (ERIG) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Netherlands Equine Rabies Immunoglobulin (ERIG) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Netherlands Equine Rabies Immunoglobulin (ERIG) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Nordic Countries Equine Rabies Immunoglobulin (ERIG) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Nordic Countries Equine Rabies Immunoglobulin (ERIG) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Nordic Countries Equine Rabies Immunoglobulin (ERIG) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. China Equine Rabies Immunoglobulin (ERIG) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. China Equine Rabies Immunoglobulin (ERIG) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. China Equine Rabies Immunoglobulin (ERIG) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Japan Equine Rabies Immunoglobulin (ERIG) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Japan Equine Rabies Immunoglobulin (ERIG) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Japan Equine Rabies Immunoglobulin (ERIG) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. South Korea Equine Rabies Immunoglobulin (ERIG) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. South Korea Equine Rabies Immunoglobulin (ERIG) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. South Korea Equine Rabies Immunoglobulin (ERIG) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. India Equine Rabies Immunoglobulin (ERIG) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. India Equine Rabies Immunoglobulin (ERIG) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. India Equine Rabies Immunoglobulin (ERIG) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Australia Equine Rabies Immunoglobulin (ERIG) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Australia Equine Rabies Immunoglobulin (ERIG) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Australia Equine Rabies Immunoglobulin (ERIG) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Southeast Asia Equine Rabies Immunoglobulin (ERIG) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Southeast Asia Equine Rabies Immunoglobulin (ERIG) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Southeast Asia Equine Rabies Immunoglobulin (ERIG) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Brazil Equine Rabies Immunoglobulin (ERIG) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Brazil Equine Rabies Immunoglobulin (ERIG) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Brazil Equine Rabies Immunoglobulin (ERIG) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Argentina Equine Rabies Immunoglobulin (ERIG) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Argentina Equine Rabies Immunoglobulin (ERIG) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Argentina Equine Rabies Immunoglobulin (ERIG) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Chile Equine Rabies Immunoglobulin (ERIG) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Chile Equine Rabies Immunoglobulin (ERIG) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Chile Equine Rabies Immunoglobulin (ERIG) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Colombia Equine Rabies Immunoglobulin (ERIG) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Colombia Equine Rabies Immunoglobulin (ERIG) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Colombia Equine Rabies Immunoglobulin (ERIG) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Peru Equine Rabies Immunoglobulin (ERIG) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Peru Equine Rabies Immunoglobulin (ERIG) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Peru Equine Rabies Immunoglobulin (ERIG) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Saudi Arabia Equine Rabies Immunoglobulin (ERIG) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Saudi Arabia Equine Rabies Immunoglobulin (ERIG) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Saudi Arabia Equine Rabies Immunoglobulin (ERIG) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Israel Equine Rabies Immunoglobulin (ERIG) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Israel Arabia Equine Rabies Immunoglobulin (ERIG) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Israel Arabia Equine Rabies Immunoglobulin (ERIG) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. UAE Equine Rabies Immunoglobulin (ERIG) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. UAE Equine Rabies Immunoglobulin (ERIG) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. UAE Equine Rabies Immunoglobulin (ERIG) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Turkey Equine Rabies Immunoglobulin (ERIG) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. Turkey Equine Rabies Immunoglobulin (ERIG) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. Turkey Equine Rabies Immunoglobulin (ERIG) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Iran Equine Rabies Immunoglobulin (ERIG) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 120. Iran Equine Rabies Immunoglobulin (ERIG) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 121. Iran Equine Rabies Immunoglobulin (ERIG) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 122. Egypt Equine Rabies Immunoglobulin (ERIG) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 123. Egypt Equine Rabies Immunoglobulin (ERIG) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 124. Egypt Equine Rabies Immunoglobulin (ERIG) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 125. Equine Rabies Immunoglobulin (ERIG) Value Chain Figure 126. Manufacturing Cost Structure Figure 127. Equine Rabies Immunoglobulin (ERIG) Sales Mode & Process Figure 128. Direct Comparison with Distribution Share Figure 129. Distributors Profiles Figure 130. Years Considered Figure 131. Research Process Figure 132. Key Executives Interviewed

Scope & coverage.

Types
  • 1500IU
  • 1000IU
  • 400IU
  • Other
Applications
  • Category II Exposure
  • Category III Exposure
Companies covered
  • Wuhan Institute of Biological Products
  • Serum China
  • Lanzhou Institute of Biological Products
  • Premium Serums
  • Haffkine Bio-Pharmaceutical
  • Bharat Serums

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Equine Rabies Immunoglobulin (ERIG) Sales Value (2021-2032)
  4. 1.2.2 Global Equine Rabies Immunoglobulin (ERIG) Sales Volume (2021-2032)
  5. 1.2.3 Global Equine Rabies Immunoglobulin (ERIG) Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Equine Rabies Immunoglobulin (ERIG) Market Dynamics
  1. 2.1 Equine Rabies Immunoglobulin (ERIG) Industry Trends
  2. 2.2 Equine Rabies Immunoglobulin (ERIG) Industry Drivers
  3. 2.3 Equine Rabies Immunoglobulin (ERIG) Industry Opportunities and Challenges
  4. 2.4 Equine Rabies Immunoglobulin (ERIG) Industry Restraints
3 Equine Rabies Immunoglobulin (ERIG) Market by Company
  1. 3.1 Global Equine Rabies Immunoglobulin (ERIG) Company Revenue Ranking in 2025
  2. 3.2 Global Equine Rabies Immunoglobulin (ERIG) Revenue by Company (2021-2026)
  3. 3.3 Global Equine Rabies Immunoglobulin (ERIG) Sales Volume by Company (2021-2026)
  4. 3.4 Global Equine Rabies Immunoglobulin (ERIG) Average Price by Company (2021-2026)
  5. 3.5 Global Equine Rabies Immunoglobulin (ERIG) Company Ranking (2024-2026)
  6. 3.6 Global Equine Rabies Immunoglobulin (ERIG) Company Manufacturing Base and Headquarters
  7. 3.7 Global Equine Rabies Immunoglobulin (ERIG) Company Product Type and Application
  8. 3.8 Global Equine Rabies Immunoglobulin (ERIG) Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Equine Rabies Immunoglobulin (ERIG) Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Equine Rabies Immunoglobulin (ERIG) Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Equine Rabies Immunoglobulin (ERIG) Market by Type
  1. 4.1 Equine Rabies Immunoglobulin (ERIG) Type Introduction
  2. 4.1.1 1500IU
  3. 4.1.2 1000IU
  4. 4.1.3 400IU
  5. 4.1.4 Other
  6. 4.2 Global Equine Rabies Immunoglobulin (ERIG) Sales Volume by Type
  7. 4.2.1 Global Equine Rabies Immunoglobulin (ERIG) Sales Volume by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Equine Rabies Immunoglobulin (ERIG) Sales Volume by Type (2021-2032)
  9. 4.2.3 Global Equine Rabies Immunoglobulin (ERIG) Sales Volume Share by Type (2021-2032)
  10. 4.3 Global Equine Rabies Immunoglobulin (ERIG) Sales Value by Type
  11. 4.3.1 Global Equine Rabies Immunoglobulin (ERIG) Sales Value by Type (2021 VS 2025 VS 2032)
  12. 4.3.2 Global Equine Rabies Immunoglobulin (ERIG) Sales Value by Type (2021-2032)
  13. 4.3.3 Global Equine Rabies Immunoglobulin (ERIG) Sales Value Share by Type (2021-2032)
5 Equine Rabies Immunoglobulin (ERIG) Market by Application
  1. 5.1 Equine Rabies Immunoglobulin (ERIG) Application Introduction
  2. 5.1.1 Category II Exposure
  3. 5.1.2 Category III Exposure
  4. 5.2 Global Equine Rabies Immunoglobulin (ERIG) Sales Volume by Application
  5. 5.2.1 Global Equine Rabies Immunoglobulin (ERIG) Sales Volume by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Equine Rabies Immunoglobulin (ERIG) Sales Volume by Application (2021-2032)
  7. 5.2.3 Global Equine Rabies Immunoglobulin (ERIG) Sales Volume Share by Application (2021-2032)
  8. 5.3 Global Equine Rabies Immunoglobulin (ERIG) Sales Value by Application
  9. 5.3.1 Global Equine Rabies Immunoglobulin (ERIG) Sales Value by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Equine Rabies Immunoglobulin (ERIG) Sales Value by Application (2021-2032)
  11. 5.3.3 Global Equine Rabies Immunoglobulin (ERIG) Sales Value Share by Application (2021-2032)
6 Equine Rabies Immunoglobulin (ERIG) Regional Sales and Value Analysis
  1. 6.1 Global Equine Rabies Immunoglobulin (ERIG) Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Equine Rabies Immunoglobulin (ERIG) Sales by Region (2021-2032)
  3. 6.2.1 Global Equine Rabies Immunoglobulin (ERIG) Sales by Region: 2021-2026
  4. 6.2.2 Global Equine Rabies Immunoglobulin (ERIG) Sales by Region (2027-2032)
  5. 6.3 Global Equine Rabies Immunoglobulin (ERIG) Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Equine Rabies Immunoglobulin (ERIG) Sales Value by Region (2021-2032)
  7. 6.4.1 Global Equine Rabies Immunoglobulin (ERIG) Sales Value by Region: 2021-2026
  8. 6.4.2 Global Equine Rabies Immunoglobulin (ERIG) Sales Value by Region (2027-2032)
  9. 6.5 Global Equine Rabies Immunoglobulin (ERIG) Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Equine Rabies Immunoglobulin (ERIG) Sales Value (2021-2032)
  12. 6.6.2 North America Equine Rabies Immunoglobulin (ERIG) Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Equine Rabies Immunoglobulin (ERIG) Sales Value (2021-2032)
  15. 6.7.2 Europe Equine Rabies Immunoglobulin (ERIG) Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Equine Rabies Immunoglobulin (ERIG) Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Equine Rabies Immunoglobulin (ERIG) Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Equine Rabies Immunoglobulin (ERIG) Sales Value (2021-2032)
  21. 6.9.2 South America Equine Rabies Immunoglobulin (ERIG) Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Equine Rabies Immunoglobulin (ERIG) Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Equine Rabies Immunoglobulin (ERIG) Sales Value Share by Country, 2025 VS 2032
7 Equine Rabies Immunoglobulin (ERIG) Country-level Sales and Value Analysis
  1. 7.1 Global Equine Rabies Immunoglobulin (ERIG) Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Equine Rabies Immunoglobulin (ERIG) Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Equine Rabies Immunoglobulin (ERIG) Sales by Country (2021-2032)
  4. 7.3.1 Global Equine Rabies Immunoglobulin (ERIG) Sales by Country (2021-2026)
  5. 7.3.2 Global Equine Rabies Immunoglobulin (ERIG) Sales by Country (2027-2032)
  6. 7.4 Global Equine Rabies Immunoglobulin (ERIG) Sales Value by Country (2021-2032)
  7. 7.4.1 Global Equine Rabies Immunoglobulin (ERIG) Sales Value by Country (2021-2026)
  8. 7.4.2 Global Equine Rabies Immunoglobulin (ERIG) Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Equine Rabies Immunoglobulin (ERIG) Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Equine Rabies Immunoglobulin (ERIG) Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Equine Rabies Immunoglobulin (ERIG) Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Equine Rabies Immunoglobulin (ERIG) Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Equine Rabies Immunoglobulin (ERIG) Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Equine Rabies Immunoglobulin (ERIG) Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Equine Rabies Immunoglobulin (ERIG) Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Equine Rabies Immunoglobulin (ERIG) Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Equine Rabies Immunoglobulin (ERIG) Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Equine Rabies Immunoglobulin (ERIG) Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Equine Rabies Immunoglobulin (ERIG) Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Equine Rabies Immunoglobulin (ERIG) Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Equine Rabies Immunoglobulin (ERIG) Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Equine Rabies Immunoglobulin (ERIG) Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Equine Rabies Immunoglobulin (ERIG) Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Equine Rabies Immunoglobulin (ERIG) Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Equine Rabies Immunoglobulin (ERIG) Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Equine Rabies Immunoglobulin (ERIG) Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Equine Rabies Immunoglobulin (ERIG) Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Equine Rabies Immunoglobulin (ERIG) Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Equine Rabies Immunoglobulin (ERIG) Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Equine Rabies Immunoglobulin (ERIG) Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Equine Rabies Immunoglobulin (ERIG) Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Equine Rabies Immunoglobulin (ERIG) Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Equine Rabies Immunoglobulin (ERIG) Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Equine Rabies Immunoglobulin (ERIG) Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Equine Rabies Immunoglobulin (ERIG) Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Equine Rabies Immunoglobulin (ERIG) Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Equine Rabies Immunoglobulin (ERIG) Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Equine Rabies Immunoglobulin (ERIG) Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Equine Rabies Immunoglobulin (ERIG) Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Equine Rabies Immunoglobulin (ERIG) Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Equine Rabies Immunoglobulin (ERIG) Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Equine Rabies Immunoglobulin (ERIG) Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Equine Rabies Immunoglobulin (ERIG) Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Equine Rabies Immunoglobulin (ERIG) Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Equine Rabies Immunoglobulin (ERIG) Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Equine Rabies Immunoglobulin (ERIG) Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Equine Rabies Immunoglobulin (ERIG) Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Equine Rabies Immunoglobulin (ERIG) Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Equine Rabies Immunoglobulin (ERIG) Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Equine Rabies Immunoglobulin (ERIG) Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Equine Rabies Immunoglobulin (ERIG) Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Equine Rabies Immunoglobulin (ERIG) Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Equine Rabies Immunoglobulin (ERIG) Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Equine Rabies Immunoglobulin (ERIG) Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Equine Rabies Immunoglobulin (ERIG) Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Equine Rabies Immunoglobulin (ERIG) Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Equine Rabies Immunoglobulin (ERIG) Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Equine Rabies Immunoglobulin (ERIG) Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Equine Rabies Immunoglobulin (ERIG) Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Equine Rabies Immunoglobulin (ERIG) Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Equine Rabies Immunoglobulin (ERIG) Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Equine Rabies Immunoglobulin (ERIG) Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Equine Rabies Immunoglobulin (ERIG) Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Equine Rabies Immunoglobulin (ERIG) Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Equine Rabies Immunoglobulin (ERIG) Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Equine Rabies Immunoglobulin (ERIG) Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Equine Rabies Immunoglobulin (ERIG) Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Equine Rabies Immunoglobulin (ERIG) Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Equine Rabies Immunoglobulin (ERIG) Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Equine Rabies Immunoglobulin (ERIG) Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Equine Rabies Immunoglobulin (ERIG) Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Equine Rabies Immunoglobulin (ERIG) Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Equine Rabies Immunoglobulin (ERIG) Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Equine Rabies Immunoglobulin (ERIG) Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Equine Rabies Immunoglobulin (ERIG) Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Equine Rabies Immunoglobulin (ERIG) Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Equine Rabies Immunoglobulin (ERIG) Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Equine Rabies Immunoglobulin (ERIG) Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Equine Rabies Immunoglobulin (ERIG) Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Equine Rabies Immunoglobulin (ERIG) Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Equine Rabies Immunoglobulin (ERIG) Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Equine Rabies Immunoglobulin (ERIG) Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Equine Rabies Immunoglobulin (ERIG) Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Equine Rabies Immunoglobulin (ERIG) Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Equine Rabies Immunoglobulin (ERIG) Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Equine Rabies Immunoglobulin (ERIG) Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Equine Rabies Immunoglobulin (ERIG) Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Equine Rabies Immunoglobulin (ERIG) Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Equine Rabies Immunoglobulin (ERIG) Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Equine Rabies Immunoglobulin (ERIG) Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Equine Rabies Immunoglobulin (ERIG) Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Equine Rabies Immunoglobulin (ERIG) Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Wuhan Institute of Biological Products
  2. 8.1.1 Wuhan Institute of Biological Products Company Information
  3. 8.1.2 Wuhan Institute of Biological Products Business Overview
  4. 8.1.3 Wuhan Institute of Biological Products Equine Rabies Immunoglobulin (ERIG) Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Wuhan Institute of Biological Products Equine Rabies Immunoglobulin (ERIG) Product Portfolio
  6. 8.1.5 Wuhan Institute of Biological Products Recent Developments
  7. 8.2 Serum China
  8. 8.2.1 Serum China Company Information
  9. 8.2.2 Serum China Business Overview
  10. 8.2.3 Serum China Equine Rabies Immunoglobulin (ERIG) Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Serum China Equine Rabies Immunoglobulin (ERIG) Product Portfolio
  12. 8.2.5 Serum China Recent Developments
  13. 8.3 Lanzhou Institute of Biological Products
  14. 8.3.1 Lanzhou Institute of Biological Products Company Information
  15. 8.3.2 Lanzhou Institute of Biological Products Business Overview
  16. 8.3.3 Lanzhou Institute of Biological Products Equine Rabies Immunoglobulin (ERIG) Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Lanzhou Institute of Biological Products Equine Rabies Immunoglobulin (ERIG) Product Portfolio
  18. 8.3.5 Lanzhou Institute of Biological Products Recent Developments
  19. 8.4 Premium Serums
  20. 8.4.1 Premium Serums Company Information
  21. 8.4.2 Premium Serums Business Overview
  22. 8.4.3 Premium Serums Equine Rabies Immunoglobulin (ERIG) Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Premium Serums Equine Rabies Immunoglobulin (ERIG) Product Portfolio
  24. 8.4.5 Premium Serums Recent Developments
  25. 8.5 Haffkine Bio-Pharmaceutical
  26. 8.5.1 Haffkine Bio-Pharmaceutical Company Information
  27. 8.5.2 Haffkine Bio-Pharmaceutical Business Overview
  28. 8.5.3 Haffkine Bio-Pharmaceutical Equine Rabies Immunoglobulin (ERIG) Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Haffkine Bio-Pharmaceutical Equine Rabies Immunoglobulin (ERIG) Product Portfolio
  30. 8.5.5 Haffkine Bio-Pharmaceutical Recent Developments
  31. 8.6 Bharat Serums
  32. 8.6.1 Bharat Serums Company Information
  33. 8.6.2 Bharat Serums Business Overview
  34. 8.6.3 Bharat Serums Equine Rabies Immunoglobulin (ERIG) Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Bharat Serums Equine Rabies Immunoglobulin (ERIG) Product Portfolio
  36. 8.6.5 Bharat Serums Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Equine Rabies Immunoglobulin (ERIG) Value Chain Analysis
  2. 9.1.1 Equine Rabies Immunoglobulin (ERIG) Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Equine Rabies Immunoglobulin (ERIG) Sales Mode & Process
  6. 9.2 Equine Rabies Immunoglobulin (ERIG) Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Equine Rabies Immunoglobulin (ERIG) Distributors
  9. 9.2.3 Equine Rabies Immunoglobulin (ERIG) Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst